Atara Biotherapeutics, Inc. (ATRA) 股票分析

公司概述

Atara Biotherapeutics, Inc. is dedicated to developing transformative therapies for patients suffering from cancer and autoimmune diseases within the United States and international markets. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, where it pursues the advancement of novel medical treatments. As of the latest available data, the entity maintains a market capitalization of $39.50 million, generates annual revenue of $120.77 million, and employs a workforce of 14 individuals. These financial metrics and operational scale indicate that the company functions as a small-cap biotechnology firm with a relatively lean organizational structure, suggesting its resources are concentrated heavily on research and development activities rather than extensive commercial overhead.

财务健康

The company reported revenue of $120.77 million over the trailing twelve months, with a corresponding net income of $32.69 million and EBITDA of $51.59 million. The significant gap between the reported revenue and net income, coupled with an operating margin of -339.6%, reveals a highly aggressive cost structure where operating expenses substantially exceed gross profit, a common characteristic in early-stage clinical development phases. Despite the negative operating margin, the entity achieved a profit margin of 27.1%, indicating potential non-operating income contributions or specific accounting adjustments affecting the bottom line. The free cash flow stands at -$47,677,624, which signifies that the company is currently burning cash to fund its operations and clinical trials, thereby limiting immediate financial flexibility for dividends or acquisitions. On the balance sheet, cash holdings of $8.48 million are lower than total debt of $10.38 million, while the debt-to-equity ratio is listed as N/A due to the negative equity position implied by the price-to-book ratio. The current ratio of 0.82 indicates that short-term assets are insufficient to cover short-term liabilities, suggesting potential liquidity constraints in the near term. Furthermore, the return on equity is N/A, whereas the return on assets stands at 47.8%, a metric that, while high, must be interpreted cautiously given the company's negative book value and the capital-intensive nature of its asset base.

估值评估

The trailing twelve-month P/E ratio is recorded at 1.88, while the forward P/E ratio is projected at 5.96. This substantial difference between the trailing and forward multiples implies that the market expects a significant divergence in future earnings compared to historical performance, although the specific trajectory driving this expectation remains to be observed within the context of the company's clinical milestones. The price-to-book ratio is -0.92, indicating that the stock trades below its book value, which often occurs in biotechnology firms where assets are largely intangible or where negative equity reflects accumulated research losses rather than fundamental insolvency. Additionally, the price-to-sales ratio is 0.33 and the EV/EBITDA multiple is 0.80, suggesting that the market values the company primarily on its revenue generation potential and EBITDA profitability rather than traditional equity metrics. The stock's trading range over the last 52 weeks spans from a low of $3.92 to a high of $19.14, providing a historical context for price volatility and potential entry points based on historical support and resistance levels. The beta coefficient of -0.33 suggests that the stock price moves inversely to the broader market trends with low volatility, presenting a unique risk profile distinct from typical biotechnology equities that usually exhibit high positive beta.

Growth & Income

The revenue growth year-over-year is reported at -95.1%, while earnings growth is listed as N/A due to the specific financial reporting conditions or lack of comparable prior period data in the dataset. The sharp decline in revenue growth indicates a contraction in sales or a shift in business model, while the absence of reported earnings growth data prevents a direct comparison of profitability expansion relative to top-line performance. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically available for reinvestment into growth initiatives such as clinical trials or R&D rather than distribution to shareholders. Consequently, the overall growth and income profile for Atara Biotherapeutics, Inc. is characterized by a lack of current income generation through dividends and a significant contraction in recent revenue figures, positioning the company as a pure-play growth asset that relies entirely on future product approvals and commercial success to restore positive cash flows and revenue trajectories.